EN CN
EN CN
FIELD COMPOUND/INDICATION Pre-clinical Phase I Phase II Phase III NDA Marketed License
Partner
License Country/
Region
Rare Disease CAN1011 (Hunterase®)Mucopolysaccharidosis type II (MPS II)
Greater China4
CAN106Multiple Genetic Disorders
Greater China4
CAN103Lysosomal Storage Disorder (LSD)
Global
CAN105Hematologic Diseases
Greater China 4
CAN104Lysosomal Storage Disorder (LSD)
Global
CAN107Metabolic Disorder
Greater China 4
Oncology CAN0022 (Caphosol®)
Oral Mucositis (OM)
China
CAN0303 (Neratinib, Nerlynx®)
HER2+ Breast Cancer Extended Adjuvant
Greater China 4
CAN0303 (Neratinib, Nerlynx®)
HER2+ Metastatic Breast Cancer >=3rd line
Greater China 4
CAN008 (CD95-Fc fusion protein)
Glioblastoma
Greater China 4
CAN017 (anti-ErbB3 mAb)
Esophageal Squamous Cell Carcinoma (ESCC)
Global
(exclude North
America)

Remarks:
1. Hunterase®is currently being marketed outside of China
2. Caphosol®is currently being marketed outside of China
3. Nerlynx®is currently being marked outside of China
4. Greater China includes China, Hong Kong, Taiwan and Macau